( CAMBRIDGE Mass.--(BUSINESS WIRE)--Jun ...)CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP,Health

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 28, 2007 - CombinatoRx, Incorporated (NASDAQ: CRXX) today announced preliminary results of its randomized, blinded, placebo-controlled clinical trial of CRx-150 in patients with rheumatoid arthritis (RA). The trial compared CRx-150 plus a disease-modifying anti-rheumatic drug (DMARD) to placebo plus DMARD (control) in subjects with active RA. In the preliminary analysis of this trial, CRx-150 demonstrated statistically significant effects on DAS28 and pain, a trend on ACR20 and no effect on CRP. -0-

Measure       Regimen     ITT Population    PP Population

------------------------------------------------------------

DAS28(a)          CRx-150   -0.51 (p=0.05)    -0.73 (p=0.07)

------------------------------------------------------------

                  Placebo           -0.05             -0.11

------------------------------------------------------------

ACR20             CRx-150     27% (p=0.13)      37% (p=0.08)

------------------------------------------------------------

                  Placebo              11%               13%

------------------------------------------------------------

CRP(a)            CRx-150       +0.25mg/L           -0.5mg/L

                                  (p=0.34)          (p=0.48)

------------------------------------------------------------

                  Placebo        -0.25mg/L          -0.2mg/L

------------------------------------------------------------

(a) Data provided are median change from baseline to day 42.

For CRx-150 treated subjects, median baseline pain as measured on a visual analogue scale (VAS), went from 63.0mm to 37.0mm at day 42, with a median change of -11.5mm, whereas placebo went from 64.5mm at baseline to 59.5mm at day 42, with a median change of -2.0mm (p=0.04).

CRx-150 was generally well tolerated. The most common adverse events in the CRx-150-treated group included headache,
'"/>

Page: 1 2 3 4 5
Related medicine technology :

1. Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139 Presented at EULAR
2. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
3. CombinatoRx to Present Combination High Throughput Screening (cHTS) Data at Upcoming AACR Meeting
4. CombinatoRx Provides Topline Results from Phase 2 RA Study with CRx-139 and Very Low Dose Prednisolone
5. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
6. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
7. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
8. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
9. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
10. PromegaExpress Expands Easy Access to Products with New Cabinet
11. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure